way too hard compared to the good fundamentals." Gilead (NASDAQ: GILD ), Celgene (NASDAQ: CELG ), Regeneron (NASDAQ: REGN ): Cramer is bullish on these stocks. Molson Coors (NYSE: TAP ): "It is in the sweet spot. That company could win on any
suit in the U.S. District Court of Delaware against Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) alleging infringement on three of its patents covering monoclonal antibodies to proprotein convertase
Gainers: ESI +17% . RADA +12% . IBIO +12% . CYTR +11% . SRPT +9% . TXT +8% . REGN +8% . SUNE +7% . SBGL +6% . NBG +5% . WLT +5% . ACHN +5% . AKS +5% . Losers: RPRX -43% . URBN -14% . PT -6% . Post your comment!
Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.
Institutes of Health and run by the Diabetic Retinopathy Clinical Research Network (DRCR.net), Regeneron's (NASDAQ: REGN ) Eylea (aflibercept) injection demonstrated a significantly greater improvement in mean change in best-corrected visual
the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday October 16. Bullish Calls: Regeneron (NASDAQ: REGN ): "I like Regeneron. It has a backer, it has new drugs, it's the future. That is where you get the good news from
By Ugly Duckling : Clinical Results Investors in Ohr Pharmaceuticals (NASDAQ: OHRP ) were taken for quite a ride on the heals of the release of interim results of the OHR-102 clinical trial. The stock gyrated as investors tried to balance the failure of the trial to attain its stated endpoint with
Allstate (NYSE: ALL ) CBS Corp. (NYSE: CBS ) Colgate-Palmolive (NYSE: CL ) Oracle (NYSE: ORCL ) Regeneron Pharmaceuticals (NASDAQ: REGN ) Schlumberger (NYSE: SLB ) Wells Fargo (NYSE: WFC ) Viacom (NASDAQ: VIAB ) Walgreen (NYSE
related macular degeneration, macular edema following retinal vein occlusion and diabetic macular edema. Related tickers: ( REGN -0.4% )( AGN +1.1% )( ALIM +1% )( OTCPK:BAYRY +0.2% )( OTCPK:BAYZF )( PSDV -4.8% ) Post your comment
By Sharon di Stefano : Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN ), recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the league of bigger players.